| Tumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15. | |
| | |
MedLine Citation:
|
PMID: 20541027 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Both the presence of HLA-DR15 and tumor necrosis factor (TNF)-α levels have been reported to affect outcome after hematopoietic cell transplantation (HCT). Patients with a myelodysplastic syndrome (MDS) show a high prevalence of HLA-DR15 and express high levels of TNF-α in the bone marrow. The present analysis involving 7950 patients showed an HLA-DR15 frequency of 31% in patients with MDS, compared with only 23% in patients with chronic myelogenous leukemia (CML). HLA-DR15 was more prevalent in Caucasian patients than in non-Caucasian patients (P = .01). The numbers of patients in the non-Caucasian subgroups were too small to allow further analysis. Among Caucasian patients with MDS and CML, the presence of HLA-DR15 did not significantly affect the occurrence of graft-versus-host disease, relapse, nonrelapse mortality (NRM), or survival. However, there was a significant correlation between DR15 and TNF polymorphisms at position -308 among patients with MDS, and the TNF-308 AG genotype conferred an increased risk of NRM compared with the GG genotype (hazard ratio [HR], 1.49; P = .02), even after adjusting for DR15. Conversely, the TNF-863 AA genotype was correlated with decreased overall mortality and NRM compared with the CC genotype (HR, 0.36, P = .04 vs HR, 0.13, P = .04), even after adjusting for DR15. There was no significant association between TNF-308 or -863 polymorphisms and transplantation outcome in CML patients. These results suggest that TNF polymorphisms, but not DR15, affect transplantation outcome in a disease-dependent manner. |
| | |
Authors:
|
Laura F Newell; Ted Gooley; John A Hansen; Derek L Stirewalt; Effie W Petersdorf; H Joachim Deeg |
Related Documents
:
|
1472927 - Glycosylated serum ferritin in patients with hematological malignancies before and afte... 12661827 - High incidence of apoptosis in peripheral blood of myelodysplastic syndrome patients de... 19648787 - No role for cerebrospinal fluid myelin basic protein levels in patients treated for chi... 3886417 - Cyclosporin a in marrow transplantation for leukemia and aplastic anemia. 11777737 - Nonresponder anorectic patients after 6 months of multimodal treatment: predictors of o... 9609417 - Sequential production of leukaemia inhibitory factor by blood cell culture in patients ... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural Date: 2010-06-09 |
Journal Detail:
|
Title: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation Volume: 16 ISSN: 1523-6536 ISO Abbreviation: Biol. Blood Marrow Transplant. Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-08 Completed Date: 2011-04-04 Revised Date: 2011-12-21 |
Medline Journal Info:
|
Nlm Unique ID: 9600628 Medline TA: Biol Blood Marrow Transplant Country: United States |
Other Details:
|
Languages: eng Pagination: 1700-6 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved. |
Affiliation:
|
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., Seattle, WA 98109, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Cohort Studies Female HLA-DR Antigens / immunology* HLA-DR Serological Subtypes Hematopoietic Stem Cell Transplantation / methods* Humans Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*, immunology, surgery* Male Middle Aged Myelodysplastic Syndromes / genetics*, immunology, surgery* Polymorphism, Genetic Retrospective Studies Transplantation, Homologous Treatment Outcome Tumor Necrosis Factors / genetics*, immunology |
| Grant Support | |
ID/Acronym/Agency:
|
AI33484/AI/NIAID NIH HHS; CA15704/CA/NCI NIH HHS; CA18029/CA/NCI NIH HHS; HL036444/HL/NHLBI NIH HHS; P01 AI033484-15/AI/NIAID NIH HHS; P01 CA018029-36/CA/NCI NIH HHS; P01 HL036444-30/HL/NHLBI NIH HHS; P30 CA015704-37/CA/NCI NIH HHS; R01 CA100019-09/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/HLA-DR Antigens; 0/HLA-DR Serological Subtypes; 0/HLA-DR15 antigen; 0/Tumor Necrosis Factors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Genetic variations of interleukin-23R (1143A>G) and BPI (A645G), but not of NOD2, are associated wit...
Next Document: Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic st...